Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung

INTRODUCTION: Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in patients with COPD having emphysema. The antimicrobial effects of AZM on the lower airway microbiome are not known and may contribute to its beneficial effects. Here we tested whether AZM treatment affects the lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Segal, Leopoldo N, Clemente, Jose C, Wu, Benjamin G, Wikoff, William R, Gao, Zhan, Li, Yonghua, Ko, Jane P, Rom, William N, Blaser, Martin J, Weiden, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Chronic Obstructive Pulmonary Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329050/
https://www.ncbi.nlm.nih.gov/pubmed/27486204
http://dx.doi.org/10.1136/thoraxjnl-2016-208599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329050/
https://www.ncbi.nlm.nih.gov/pubmed/27486204
http://dx.doi.org/10.1136/thoraxjnl-2016-208599

Ejemplares similares